Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine
Reference41 articles.
1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017
2. Immune checkpoint inhibitors in non-small cell lung cancer;Herzberg;Oncologist,2017
3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017
4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016
5. Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy;Jean;Ther Adv Med Oncol,2017